Form 4: DiaMedica Therapeutics: Jan Stahlberg and Trill AB Increase Stake with $3 Million Share Purchase

Jan Stahlberg, through Trill AB, acquires 1,200,000 common shares of DiaMedica Therapeutics at $2.50 per share, increasing their total holdings.

Summary

• On June 28, 2024, Jan Stahlberg, indirectly through Trill AB, purchased 1,200,000 common shares of DiaMedica Therapeutics Inc. (DMAC) at a price of $2.50 per share.
• The total value of this transaction is $3,000,000.
• Following the transaction, Stahlberg, through Trill AB, beneficially owns 5,221,608 shares.
• These shares are directly owned by Trill AB, and Stahlberg has sole voting and disposal power as the board member and sole owner of Trill AB.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the significant share purchase by a director, indicating confidence in the company's prospects. However, it's a single transaction and doesn't provide a comprehensive view of the company's overall health.

Positives

• The purchase indicates confidence in DiaMedica Therapeutics by a significant shareholder.
• Increased ownership by a board member can align interests with other shareholders.

Industry Context

Insider buying can often be seen as a positive signal in the market, suggesting that those with the most knowledge of the company's prospects are optimistic about its future. This transaction could influence investor sentiment towards DiaMedica Therapeutics.

Stakeholder Impact

• Shareholders may view the purchase positively, potentially leading to increased investor confidence.
• The increased stake by a board member could align management's interests more closely with those of shareholders.

Key Dates